GNPX - Genprex: Limited Clinical Data To Justify Risk

• GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes.
• REQORSA—the company's main pipeline molecule—is targeting the Non-Small-Cell Lung Cancer Market.
• GNPX's share price is currently trading at around $2 after a quick fall from grace (from $15/share) following its IPO in early 2018.
• Although a low share price may be an attractive entry point, I believe the company has not yet produced any reliable proof of the clinical efficacy of its therapy.
• In this article, I will argue a neutral position on GNPX discussing the company's technology, market, and clinical data, to present a balanced view on both risk and opportunity.

For further details see: